Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Lung Cancer. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

Published in Lung Cancer

Expert Opinion / Cases · December 03, 2021

Isolated CNS Recurrence After Definitive Therapy for Stage III NSCLC

Written by
Michael J. Grant MD


Discuss This item Follow

No comments yet, be the first to start the discussion!

  • marco buso

    Dec 10, 2021

    Whole brain radiotherapy
    No systemic therapy, surveillance imaging

  • Leoncio Arribas Alpuente

    Dec 10, 2021

    WBRT plus concomitant boost, without systemic therapy if only had brain metastasis

  • Jean-Yves Douillard

    Feb 11, 2022

    This case should be discussed in MDT with a radiation oncologist. 
    The patient is 75, he has brain metastasis as a single organ site. Based on the number of metastatic lesions, I would favour Whole Brain Radiotherapy. After re-evaluation of the brain and in the absence of disease progression at other sites, in a discussion with the patient, I would suggest no further systemic therapy, surveillance imaging and would wait for documented relapse to start another treatment depending on the clinical presentation.

  • May 18, 2024

    Pending Moderator approval.

Further Reading